Acute and Long-Term Immune-Treatment Strategies in Anti-LGI1 Antibody–Mediated Encephalitis
Authors:
- Nabil SeeryNSNabil Seery
- Robb WesselinghRWRobb Wesselingh
- Paul BeechPBPaul Beech
- Laurie M. McLaughlinLMLaurie M. McLaughlin
- Tiffany RushenTRTiffany Rushen
- Amy J. HallidayAHAmy J. Halliday
- Liora ter HorstLHLiora ter Horst
- Sarah P. GriffithSGSarah P. Griffith
- Mirasol ForcadelaMFMirasol Forcadela
- Tracie H. TanTTTracie H. Tan
- Christina KazziCKChristina Kazzi
- Cassie NesbittCNCassie Nesbitt
Open Access
- 1 July 2025
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 12 (4) , e200412
Abstract
Few studies have evaluated acute immunotherapy and relapse prevention strategies in patients with anti-leucine-rich glioma-inactivated 1 (LGI1) antibody (Ab)-mediated encephalitis. The objective of this study was to analyze the outcomes of acute and long-term immunotherapy strategies in this population. We undertook a multicenter cohort study of 55 patients with anti-LGI1 Ab-mediated encephalitis, either recruited prospectively or identified retrospectively from 10 Australian hospitals as part of the Australian Autoimmune Encephalitis Consortium. Clinical data were collected, including treatment durations of all relevant immunotherapies. Clinical outcomes that we examined included (1) time to first clinical relapse, (2) improvement on modified Rankin Scale (mRS), and (3) favorable binary composite clinical-functional outcome at 12 months. A favorable outcome was defined as fulfilling all three of mRS less than 3, a score of 1 or less in the memory dysfunction component of the Clinical Assessment Scale in Autoimmune Encephalitis, and absence of drug-resistant epilepsy. Rituximab, adjusted for concomitant use of other immunotherapies, was associated with increased time to first relapse (hazard ratio 0.10; 95% CI 0.001-0.85; p = 0.03). Intravenous pulsed methylprednisolone was associated with an improvement in mRS (OR 4.48; 95% CI 1.03-21.3; p = 0.048) and a favorable composite clinical-functional outcome (OR 4.96; 95% CI 1.07-27.2; p = 0.049) at 12 months. Rituximab may be effective at preventing relapses in patients with anti-LGI1 Ab-mediated encephalitis. Acute methylprednisolone treatment may be associated with favorable outcomes at 12 months. This study provides Class IV evidence that for patients with anti-LGI1 Ab-mediated encephalitis, rituximab prevents relapses and acute methylprednisolone is associated with favorable outcomes at 12 months.Keywords
This publication has 38 references indexed in Scilit:
- Anti-LGI1 encephalitisNeurology, 2016
- Anti-LGI1–associated cognitive impairmentNeurology, 2016
- A definition and classification of status epilepticus – Report of theILAETask Force on Classification of Status EpilepticusEpilepsia, 2015
- Effect of Rituximab in Patients With Leucine-Rich, Glioma-Inactivated 1 Antibody–Associated EncephalopathyJAMA Neurology, 2014
- Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort studyThe Lancet Neurology, 2013
- Late‐onset neutropenia following rituximab therapy in rheumatic diseases: Association with B lymphocyte depletion and infectionsArthritis & Rheumatism, 2011
- Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic StrategiesEpilepsia, 2010
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009
- Avoiding infinite estimates of time‐dependent effects in small‐sample survival studiesStatistics in Medicine, 2008
- Interobserver agreement for the assessment of handicap in stroke patients.Stroke, 1988